Author(s):
Naveen Kumar, Prerna Sarup, Sonia Pahuja
Email(s):
bhardwajnaveeen97@yahoo.com
DOI:
10.52711/0974-360X.2021.00495 
Address:
Naveen Kumar*, Prerna Sarup, Sonia Pahuja
Department of Pharmaceutics, Swami Vivekanand College of Pharmacy, Banur, Punjab, India 140601.
*Corresponding Author
Published In:
Volume - 14,
Issue - 5,
Year - 2021
ABSTRACT:
The objective was to formulate rapid dispersible tablets of Cefpodoxime Proxetil using various types of superdisintegrants viz., Croscarmellose sodium (CCS), Sodium starch glycolate (SSG) and Crospovidone (CP) in varied concentrations (1-5%). The model drug for current investigation, Cefpodoxime Proxetil, a broad spectrum third generation Cephalosporin antibiotic belongs to BCS class IV. The preformulation studies were accomplished by determining the compatibility of model drug with respective excipients by FTIR studies. These studies, revealed no chemical interaction of excipients with the model drug. The formulation development was achieved in phases comprising of preliminary screening, pre-optimization and optimization studies. The bitter taste of model drug was masked by addition of flavors and sweeteners to make it pleasant for pediatric patients upon oral administration. The formulations (F1-F6) were prepared by direct compression method. The percent released from all formulations showed release of more than 90% of drug within 30 min with drug content of more than 95%. The study showed that formulation containing CCS as superdisintegrants furnished best results. Formulation F5 showed maximum (99.6%) drug release within 30 minutes which is prerequisite for dispersible tablets. It also possessed a rapid release of drug from the formulation. The F5 formulation showed comparative dissolution profile vis-a-vis a commercialized formulation. The study concluded that dispersible tablets of Cefpodoxime Proxetil can be an alternative to conventional dosage form for the treatment of urinary tract infection, skin infection, and upper respiratory tract infections.q
Cite this article:
Naveen Kumar, Prerna Sarup, Sonia Pahuja. Formulation and Characterization of Dispersible Tablets of Cefpodoxime Proxetil: A Cephalosporin Antibiotic. Research Journal of Pharmacy and Technology. 2021; 14(5):2806-3. doi: 10.52711/0974-360X.2021.00495
Cite(Electronic):
Naveen Kumar, Prerna Sarup, Sonia Pahuja. Formulation and Characterization of Dispersible Tablets of Cefpodoxime Proxetil: A Cephalosporin Antibiotic. Research Journal of Pharmacy and Technology. 2021; 14(5):2806-3. doi: 10.52711/0974-360X.2021.00495 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-5-79
REFERENCES:
1. Chintan B, Kailash Y, Tarachand K, Shah H, Bhatt D, Shah C, et al. Formulation Development and Evaluation of the Dispersible Tablet of Cefpodoxime Proxetil. Int. J. Pharm. Res. Tech. 2012; 3(1): 06-10.
2. Mostafa G. A.E., Al-Otaibi Y. H., and Al-Badr A.A., Cefpodoxime proxetil. In H. G. Brittain, Profiles of Drug Substances, Excipients and Related Methodology (Vol. 44). Cambridge, Zoe Kruze: 2019: 1-165.
3. Nina Krajcar, Lorna Stemberger Marić, Dalibor Šarić, Neven Milić, Goran Tešović. Cefpodoxime Proxetil as a therapeutic option in switching therapy for infective endocarditis in children: case reports and literature review. J. Chemother. 2019; 31(6): 354-358.
4. Todd MW. Cefpodoxime Proxetil: A comprehensive review. Int. J. Antimicrob. Agents. 1994; 4(1): 37–62.
5. Bergogne-Bérézin E. International clinical experience with Cefpodoxime Proxetil. Curr. Ther. Res. 1996; 57(13): 103-116.
6. Frampton J, Brogden R, Langtry H, Buckley M. Cefpodoxime Proxetil: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1992; 44(5): 889-917.
7. Gupta S, Chandel P, Bagga K. Formulation and Evaluation of Cefpodoxime Proxetil dispersible tablets. Int. J. Pharm. Sci. Rev. 2014; 27(2): 250-255.
8. Kumar N, Pahuja S. Dispersible Tablets: An Overview. J. Med. Pharm. Allied Sci. 2019; 8(3): 2175-2191.
9. Gupta SP, Bashyal P, Shrestha L. Formulation And Evaluation Of Oral Dispersible Tablets Of Loratadine By Direct Compression Method. World J. Pharm. Pharm. Sci. 2019; 8 (4): 1352-1370.
10. Ravin, L., Radebaugh, G. Preformulation. In J. Remington, and A. Gennaro, Remington’s Pharmaceutical Sciences (18 ed.). Easton, Pennsylvania: Mack Publishing Company. 1990.
11. Banker G, Anderson N. Tablets. In L. Lachman, H. Lieberman, and J. Kanig, The Theory and Practice of Industrial Pharmacy (3 ed.). Bombay: Varghese publishing house. 1987: 293-345
12. Colthup N, Daly L, Wiberley S. Introduction to Infrared and Raman Spectroscopy (3rd ed.). Academic Press, 1990.
13. Brahmankar D, Jaiswal S. Absorption of drugs Biopharmaceutics and Pharmacokinetics-A treatise (1 ed.). Delhi: Vallabh Prakashan, 1999.
14. Chaturvedi H, Garg A, Rathore US. Post-Compression Evaluation Parameters For Tablets-An Overview. Eur. J. Pharm. Med. Res. 2017; 4(11): 526-530.
15. Fathima S, Sridhar R. Formulation and Evaluation of Clonazepam Oro Dispersible Tablets, J. Drug Dev. Del. 2019; 2(1): 19-24.
16. Chattoraj S, Sun CC. Crystal and particle engineering strategies for improving power compression and flow properties to enable continuous tablet manufacturing by direct compression. J. Pharm. Sci. 2018; 107: 968-974.
17. Bowles BJ, Dziemidowicz K, Lopez FL, Orlu M, Tuleu C, Edwards AJ, Ernest TB. Co-processed Excipients for dispersible tablets- part 1: Manufacturability. AAPS Pharm Sci Tech. 2018; 19: 2598-2609.
18. Nandhini J, Rajalakshmi, A. Dispersible Tablets: A Review. J. Pharm. Adv. Res. 2018;1 (3): 148-155.
19. Mohan G, Sheri PS, Kuriachan, MA. Formulation and Evaluation of Orodispersible Tablet of Esomeprazole. Int. J. Pharm. Pharm. Res. 2018; 12 (3): 340-366.
20. Kadam SV, Rane N U, Magdum C S. Formulation and Evaluation of Orodispersible Tablets of Levamisole Hydrochloride. Asian J. Pharm. Tech. 2019. 9 (2): 63-68.